Literature DB >> 25331796

Modulation of liver-intestine cadherin (Cadherin 17) expression, ERK phosphorylation and WNT signaling in EPHB6 receptor-expressing MDA-MB-231 cells.

Lokesh Bhushan1, Nadia Tavitian1, Dilip Dey1, Zohra Tumur2, Cyrus Parsa3, Raj P Kandpal1.   

Abstract

Aberrant expression of erythropoietin-producing hepatocellular carcinoma cell (EPH) receptors has been reported in a variety of human cancer types. In addition to modulating cell proliferation and migration, EPH receptors are also involved in tumor progression. The transcriptional activation and silencing of EPH receptors are also associated with tumorigenesis. However, the mechanisms underlying the involvement of EPH receptors in tumorigenesis have not been completely deciphered. We have investigated and described the role of EPHB6, a kinase-deficient receptor, in modulating the abundance of cadherin 17 and activation of other intracellular signaling proteins. We previously showed that EPHB6 alters the tumor phenotype of breast carcinoma cells. However, the mechanisms underlying these phenotypic changes had not previously been investigated. Herein we demonstrated the downstream effects of EPHB6 expression on the abundance of cadherin 17, mitogen-activated protein kinase (MEK2), extracellular signal-regulated kinase (ERK), phospho-ERK, β-catenin, phospho- glycogen synthase kinase 3 beta (GSK3β) (ser21/9), cell morphology and actin cytoskeleton. These comparisons were made between EPHB6-deficient MDA-MB-231 cells transfected with an empty pcDNA3 vector and cells stably transfected with an expression construct of EPHB6. The results indicate elevated levels of MEK2 and phospho-ERK. While there was no change in the amount of ERK, the abundance of cadherin 17, β-catenin and phospho-GSK3β was significantly reduced in EPHB6-transfected cells. These studies clearly demonstrate an inverse relationship between the levels of phospho-ERK and the abundance of cadherin 17, β-catenin and phospho-GSK3β in EPHB6-expressing MDA-MB-231 cells. From these data we conclude that EPHB6-mediated alterations arise due to changes in abundance and localization of cadherin 17 and activation of WNT signaling pathway. Transcriptional silencing of EPHB6 in native MDA-MB-231 cells and consequent effects on cadherin 17 and WNT pathway may, thus, be responsible for the invasive behavior of these cells. Copyright
© 2014, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved.

Entities:  

Keywords:  CDH17; EPHB6; ERK; GSK3β; WNT; breast carcinoma; cadherin 17; β-catenin

Mesh:

Substances:

Year:  2014        PMID: 25331796

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  6 in total

1.  Expression of Cadherin-17 Promotes Metastasis in a Highly Bone Marrow Metastatic Murine Breast Cancer Model.

Authors:  Tomoko Okada; Atsushi Kurabayashi; Nobuyoshi Akimitsu; Mutsuo Furihata
Journal:  Biomed Res Int       Date:  2017-01-19       Impact factor: 3.411

2.  Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.

Authors:  James M Paul; Behzad Toosi; Frederick S Vizeacoumar; Kalpana Kalyanasundaram Bhanumathy; Yue Li; Courtney Gerger; Amr El Zawily; Tanya Freywald; Deborah H Anderson; Darrell Mousseau; Rani Kanthan; Zhaolei Zhang; Franco J Vizeacoumar; Andrew Freywald
Journal:  Oncotarget       Date:  2016-08-02

3.  The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation.

Authors:  Amr M El Zawily; Behzad M Toosi; Tanya Freywald; Vijaya V Indukuri; Franco J Vizeacoumar; Scot C Leary; Andrew Freywald
Journal:  Oncotarget       Date:  2016-11-22

Review 4.  Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers.

Authors:  Chung-Ting Jimmy Kou; Raj P Kandpal
Journal:  Biomed Res Int       Date:  2018-02-28       Impact factor: 3.411

5.  EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.

Authors:  Behzad M Toosi; Amr El Zawily; Luke Truitt; Matthew Shannon; Odette Allonby; Mohan Babu; John DeCoteau; Darrell Mousseau; Mohsin Ali; Tanya Freywald; Amanda Gall; Frederick S Vizeacoumar; Morgan W Kirzinger; C Ronald Geyer; Deborah H Anderson; TaeHyung Kim; Alana L Welm; Peter Siegel; Franco J Vizeacoumar; Anthony Kusalik; Andrew Freywald
Journal:  Oncogene       Date:  2018-04-27       Impact factor: 9.867

6.  A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.

Authors:  Alexandre de Nonneville; Pascal Finetti; José Adelaide; Éric Lambaudie; Patrice Viens; Anthony Gonçalves; Daniel Birnbaum; Emilie Mamessier; François Bertucci
Journal:  Cancers (Basel)       Date:  2019-08-13       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.